RhumbLine Advisers
SPRB

RhumbLine Advisers’s Spruce Biosciences SPRB Stock Holding History

RhumbLine Advisers’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$190K Buy
+3,519
New +$197K ﹤0.01% 3307

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return

RhumbLine Advisers's SPRB Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Spruce Biosciences (SPRB) in Q2 2026: 3,519 shares worth $190K. The stake represents ﹤0.01% of the portfolio and ranks #3307 among its holdings.

57 funds tracked by Wall St. Rank hold SPRB as of Q2 2026.

  • RhumbLine Advisers held 3,519 shares of Spruce Biosciences worth $190K as of Q2 2026.
  • Spruce Biosciences was a new RhumbLine Advisers position in Q2 2026.
  • Spruce Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3307 holding.
  • 57 funds tracked by Wall St. Rank held Spruce Biosciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.